Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)
Completed
- Conditions
- HypercholesterolemiaFamilial HypercholesterolemiaHomozygous Sitosterolemia
- Interventions
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 11332
- Registration Number
- NCT00704444
Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)
Completed
- Conditions
- Rhinitis
- Interventions
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 591
- Registration Number
- NCT00704769
Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)
Completed
- Conditions
- Homozygous Familial HypercholesterolemiaPrimary Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 4105
- Registration Number
- NCT00704535
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)
Completed
- Conditions
- Pregnancy
- Interventions
- Drug: Org 36286 (corifollitropin alfa)Drug: PlaceboDrug: recFSH
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 29
- Registration Number
- NCT00702195
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)
Completed
- Conditions
- PregnancyNeonates
- Interventions
- Drug: Corifollitropin Alfa 150 μgBiological: 200 IU RecFSH/Follitropin beta (Days 1 to 7)Drug: Placebo for RecFSH/Follitropin betaDrug: Placebo for Corifollitropin AlfaBiological: 200 IU RecFSH/Follitropin beta (Days 8 to hCG)Drug: GanirelixBiological: hCGBiological: Progesterone
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 541
- Registration Number
- NCT00703014
Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)
Phase 2
Completed
- Conditions
- Infertility
- Interventions
- Drug: Org 36286Drug: Placebo
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 55
- Registration Number
- NCT00702585
Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)
Completed
- Conditions
- In Vitro Fertilization
- Interventions
- Drug: 150 µg Corifollitropin AlfaBiological: 200 IU RecFSH/Follitropin beta (Days 1 to 7)Drug: Placebo for RecFSH/Follitropin betaDrug: Placebo for Corifollitropin AlfaBiological: 200 IU RecFSH/Follitropin beta (Days 8 to hCG)Drug: GanirelixBiological: hCGBiological: Progesterone
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 344
- Registration Number
- NCT00702273
To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)
Phase 3
Completed
- Conditions
- Infertility
- Interventions
- Drug: corifollitropin alfa (Org 36286)Drug: recFSH (follitropin beta)Drug: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)Drug: human chorion gonadatropin (hCG)Biological: progesteroneDrug: placebo-recFSH (follitropin alfa)Drug: placebo-corifollitropin alfaBiological: open-label recFSH
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 397
- Registration Number
- NCT00702845
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)
Completed
- Conditions
- PregnancyNeonates
- Interventions
- Drug: corifollitropin alfaBiological: recombinant Follicle Stimulating Hormone (recFSH)Biological: human Chorion Gonadotropin (hCG)Biological: hCG Bolus injection
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1
- Registration Number
- NCT00702338
Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)
Phase 2
Completed
- Conditions
- In Vitro FertilizationInfertility
- Interventions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 99
- Registration Number
- NCT00702806
© Copyright 2025. All Rights Reserved by MedPath